RG 2833

Drug Profile

RG 2833

Alternative Names: RG-FA; RG2833; RGFP-109

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator The Scripps Research Institute
  • Developer Repligen Corporation
  • Class Small molecules
  • Mechanism of Action HDAC3 protein inhibitors; Transcription factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Friedreich's ataxia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Friedreich's ataxia

Highest Development Phases

  • No development reported Friedreich's ataxia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Friedreich's ataxia in Italy (PO)
  • 16 Mar 2012 RG 2833 is available for licensing in World as of 10 Jun 2011.
  • 15 Mar 2012 Phase-I clinical trials in Friedreich's ataxia in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top